J&J One-Shot Vaccine Is Safe In Early Trials, Generates "Promising Immune Response" | ZeroHedge

added 14.01.2021 00:21

Share

Speaking to CNBC’s Meg Tirrell, Dr. Paul Stoffels, chief scientific officer at J&J said that the phase one and two clinical trial data shows a single shot of the vaccine “gives sustainable antibodies.”

Unlike Pfizer’s and Moderna’s authorized vaccines, which require two doses about three to four weeks apart, J&J’s requires only one dose.

By day 57, all volunteers had detectable antibodies, regardless of vaccine dose or age group, and remained stable for at least 71 days in the 18-to-55 age group.

According tot he report, J&J scientists randomly assigned healthy adults between the ages of 18 and 55 and those 65 and older to receive a high or low dose of its vaccine - called Ad26.COV2.S - or a placebo.

Similar Posts